Study guide
5.4 Non-Sterile Compounding Standards
California Practice Standards and Jurisprudence Examination for Pharmacists CPJE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Information & Prescription Evaluation (Domain 1)
1.1 Patient Profile & Health Data Acquisition 1.2 Prescription Authenticity & Prescriber Authority 1.3 California Security Prescription Forms & E-Prescribing Mandates (B&P § 688) 1.4 Clinical Evaluation of Dosing & Organ Impairment 1.5 Drug-Drug & CYP450 Interactions 1.6 Special Populations & High-Risk Medications 1.7 Physical Assessment & Health Screening 1.8 Final Check, Labeling Verification & Product Selection Workflow
2 Chapter 2: Clinical Practice & Disease State Management (Domain 2: Clinical Practice & Jurisprudence)
2.1 Cardiovascular Therapeutics & Clinical Law 2.2 Endocrine & Metabolic Disorders 2.3 Respiratory & Infectious Disease Management 2.4 Central Nervous System & Pain Management 2.5 Oncology, Immunology & Specialty Pharmacy 2.6 Medication Therapy Management & Collaborative Goals of Therapy 2.7 Formulary Systems, Therapeutic Interchange & Medication Affordability 2.8 Medication Reconciliation & Ordering Monitoring Procedures
3 Chapter 3: California Pharmacy Jurisprudence & Prescriptive Authority (Domain 2: Clinical Practice & Jurisprudence)
3.1 Controlled Substances & CURES PDMP 3.2 Controlled Substance Dispensing, Refills, & Partial Fills 3.3 Independent Pharmacist Furnishing Scope 3.4 Advanced Pharmacist Practitioner (APP/APh) & CDTM 3.5 Immunization Authority & CAIR Reporting 3.6 Patient Counseling & Patient-Centered Labeling 2.9 OTC, CAM, Lifestyle Counseling & Teach-Back 2.10 Educating Health Professionals & Supplemental Patient Information
4 Chapter 4: Pharmacy Operations, Board Governance & Personnel (Domain 3: Pharmacy Operations & Jurisprudence)
California Board of Pharmacy Governance & Licensure Pharmacist Continuing Education & License Maintenance Pharmacist-in-Charge (PIC) & Pharmacy Ownership Pharmacy Personnel & Supervision Ratios Pharmacy Security, Theft, & Diversion Reporting 4.6 Controlled Substance Inventory & Record Reconciliation 4.7 Quality Assurance, Medication Error Systems & ADR Reporting 4.8 Privacy, Confidentiality & Pharmacy Policies and Procedures
5 Chapter 5: Drug Supply Chain, Dispensing & Compounding Regulations (Domain 3: Pharmacy Operations & Jurisprudence)
5.1 Drug Procurement, DSCSA Track & Trace, & Storage 5.2 Generic Substitution, Bioequivalence, & Orange Book 5.3 Prescription Transfer, Refills, & Off-Site Dispensing 5.4 Non-Sterile Compounding Standards 5.5 Sterile Compounding & Hazardous Drug Handling 5.6 Emergency Preparedness & Continuity of Pharmacy Operations
5.4 Non-Sterile Compounding Standards
Key Takeaways Explain This Topic AI
Non-sterile compounding in California is governed by 16 CCR § 1735 and USP <795>.
Compounding differs from manufacturing as it is patient-specific and based on a valid prescription.
A Master Formula Record is the recipe, while the Compounding Record is the log of what was actually made.
Beyond-Use Dates (BUDs) vary by formulation: 6 months (non-aqueous), 14 days refrigerated (water-containing oral), 30 days (water-containing topical).
Last updated: July 2026
- 5.4 Non-Sterile Compounding Standards
- Compounding vs. Manufacturing
Compounding is the preparation, mixing, assembling, packaging, or labeling of a drug or device in accordance with a licensed practitioner's prescription under an initiative based on the practitioner/patient/pharmacist/compounder relationship in the course of professional practice.
The distinction between compounding and manufacturing is critical.
Compounding is patient-specific, small-scale, and regulated primarily by state boards of pharmacy (under 503A of the Food, Drug, and Cosmetic Act).
Manufacturing involves large-scale production of non-patient-specific drugs for resale, which is highly regulated by the FDA (requiring Current Good Manufacturing Practices, CGMP).
In California, a pharmacy may compound a reasonable quantity of a drug in anticipation of receiving prescriptions (anticipatory compounding) based on historical dispensing patterns, but the drug cannot be dispensed until a valid patient-specific prescription is received. Such compounding is an essential service for patients who cannot tolerate commercially available forms, need custom strengths, or have allergies to certain excipients used in manufactured products.
Regulations: 16 CCR § 1735 and USP <795>
Non-sterile compounding in California is governed by the California Code of Regulations (16 CCR § 1735 series) and the United States Pharmacopeia (USP) General Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations. These standards ensure that compounded preparations are of acceptable strength, quality, and purity.
Non-sterile compounding typically involves creating oral liquids, topical creams, ointments, suppositories, and capsules. It must take place in a designated area of the pharmacy that is clean, well-lit, and maintained in a good state of repair, separate from dispensing and counseling areas.
Documentation: Master Formula and Compounding Record
Strict documentation is the backbone of safe compounding. Pharmacies must maintain two primary documents for every compounded preparation:
1. Master Formula Record (The "Recipe")
The Master Formula Record is the standardized "recipe" that provides step-by-step instructions on how to prepare the compounded drug. It ensures consistency from batch to batch. It must include:
Active ingredients and excipients.
Equipment required.
Specific step-by-step compounding instructions.
Expected yield.
Quality control procedures and specifications (e.g., appearance, pH).
Container-closure system requirements.
Assigned Beyond-Use Date (BUD) criteria.
2. Compounding Record (The "Log")
The Compounding Record documents the actual execution of the Master Formula for a specific batch. It proves that the formula was followed. It must include:
Name, strength, and dosage form of the preparation.
Master Formula Record reference.
Date and time of compounding.
Identity of the personnel who compounded the preparation and the pharmacist who verified it.
Vendor, lot numbers, and expiration dates of all ingredients used.
Total quantity compounded.
Assigned prescription number(s) and assigned BUD.
Results of quality control procedures.
Creating comprehensive compounding records requires tremendous attention to detail. A missing lot number or expiration date for a single ingredient invalidates the entire record. California inspectors routinely audit these logs to verify that the math checks out, the equipment used was appropriate, and all safety checks were successfully documented.
Beyond-Use Dates (BUDs)
A Beyond-Use Date (BUD) is the date after which a compounded preparation shall not be used. It is fundamentally different from a manufacturer's expiration date. Expiration dates are determined through rigorous, long-term stability testing by manufacturers. BUDs are assigned by the pharmacist based on the physical and chemical stability of the specific compounded formulation, relying on literature and USP guidelines.
USP <795> provides default maximum BUDs for non-sterile compounded preparations, assuming they are packaged in tight, light-resistant containers and stored at controlled room temperature (unless otherwise specified). Pharmacists must assign the following BUDs, or the earliest expiration date of any ingredient used , whichever is shorter:
- Type of Formulation Maximum BUD (Default USP <795>) Storage Condition
- Non-Aqueous Formulations (e.g., ointments, capsules, powders) 6 months (180 days) Room temperature
- Water-Containing Oral Formulations (e.g., oral suspensions, solutions) 14 days Refrigerator (2°C to 8°C)
Water-Containing Topical/Dermal and Mucosal Liquid and Semisolid Formulations (e.g., creams, gels) 30 days Room temperature
Note: These are maximum default BUDs. If a pharmacy has specific stability testing data (e.g., from an analytical laboratory) for their exact formulation and container, they may extend the BUD beyond these defaults, but they must have the documentation to prove it.
Determining the correct BUD demands a thorough understanding of physical chemistry and pharmacology. When compounding a preparation containing multiple active pharmaceutical ingredients (APIs), the interaction between these components must be scrutinized. The presence of water invariably reduces stability, making aqueous oral formulations the most perishable among non-sterile compounds. This emphasizes the importance of patient counseling, ensuring they understand proper storage and when to discard unused portions.
Quality Assurance, Equipment, and Training
Quality Assurance (QA): Pharmacies must have a written QA plan that defines how they monitor and evaluate compounding processes. This includes steps for investigating any compounding errors or adverse events reported by patients. The QA process must be fully documented and subjected to periodic review by the pharmacist-in-charge (PIC).
Equipment: All equipment (e.g., balances, trituration tools, homogenizers) must be appropriately designed, adequately sized, and suitably located to facilitate operation for its intended use. Balances must be calibrated regularly, and documentation of calibration must be maintained. Only specific pharmaceutical-grade mortars and pestles, typically made of glass, wedgwood, or porcelain, should be employed, depending on the abrasive nature of the ingredients.
Personnel Training: Any pharmacy personnel engaging in compounding must be thoroughly trained and evaluated. The pharmacist-in-charge (PIC) is responsible for ensuring that all staff have demonstrated competence in compounding techniques, pharmaceutical calculations, and the use of compounding equipment before they are allowed to prepare medications. This training must be documented and repeated at least annually. Such rigor guarantees that personnel are fully capable of reading a Master Formula and executing it accurately.